The company has finalized several optimization cycles for its proprietary AI system, which now processes multidimensional inputs ranging from medication history and diagnosis to patient behavioral patterns. By feeding clinical data back into the architecture, the system creates a closed-loop environment where algorithms refine risk identification and personalize intervention strategies. This shift is intended to transition the business from standard healthcare services toward data-driven, predictive management.

Simultaneously, the firm is leveraging its RWD ecosystem to fuel pharmaceutical research and evidence-based studies. These services now represent a core pillar of the company's four-tier revenue structure, utilizing insurance and physiological data to support third-party collaborations. Chairman and CEO Zhenyang Shi noted that the firm is focused on translating these technical capabilities into practical, deployable solutions within real-world clinical scenarios. Through its physician network, Pomdoctor is currently testing integrated management pilots designed to bridge the gap between in-hospital treatment and out-of-hospital follow-up.